Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01668537 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 651
- Enrollment target
NCT01668537 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 651 participants.
The verdict
NCT01668537, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 651 participants
- Enrollment target
Study Summary
A randomized, double-blind, multicenter Phase II trial to compare the immunogenicity and safety of a liquid-frozen and a freeze-dried formulation of IMVAMUNE (MVA-BN®) smallpox vaccine in vaccinia-naïve healthy subjects
Interventions
- BIOLOGICAL LF formulation of IMVAMUNE®
- BIOLOGICAL FD formulation of IMVAMUNE®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 651 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01668537
The ClinicalTrials.gov registry entry for NCT01668537 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 651 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LF formulation of IMVAMUNE® is the first listed.
NCT01668537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01668537 about?
NCT01668537 is a clinical study titled "A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects". A randomized, double-blind, multicenter Phase II trial to compare the immunogenicity and safety of a liquid-frozen and a freeze-dried formulation of IMVAMUNE (MVA-BN®) smallpox vaccine in vaccinia-naïve healthy subjects
What is the current status of trial NCT01668537?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 651 participants. The study started on 2013-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01668537?
The interventions under investigation include: LF formulation of IMVAMUNE® (BIOLOGICAL), FD formulation of IMVAMUNE® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01668537?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.